Background: Previous studies in non-small cell lung cancer (NSCLC) on programmed cell death ligand 1 (PD-L1) expression and its role in prognosis led to conflicting results. For treatment plan after CCRT, we sought to analyze PD-L1 expression and CD8þ lymphocyte and their relation with prognosis in stage III NSCLC patients treated with neo adjuvant CCRT followed by surgery with curative aim. Methods: We retrospectively enrolled 43 patients with stage III NSCLC treated with neo adjuvant CCRT followed by surgery at Yonsei Cancer Center Severance hospital, between June 2008 and October 2010. Immunohistochemistry (IHC) was performed on tissue sections of PD-L1 expression and presence of stromal CD8þ lymphocytes in NSCLC specimens. Weekly standard chemotherapy based on platinum was included in CCRT.
Results: The median age of patients at diagnosis was 62 years. Thirty patients (70%) were males and 13 patients (30%) were females. Never smokers were 17 patients (40%). Twenty-five patients had squamous cell carcinoma (58%). The post-CCRT PD-L1-positive group exhibited a tendency of poorer recurrence free survival (RFS) compared to post CCRT PD-L1-negative group (p ¼ 0.108). The overall survival (OS) also showed a similar trend (p ¼ 0.215). In the survival analysis with pre-CCRT specimens, both RFS and OS analyses showed no statistically significant differences (p ¼ 0.423). Although it was not statistically significant, in a group showed increase in PD-L1 expression after CCRT resulted in the steepest curve in OS analysis (p ¼ 0.220). Increase in stromal CD8þ lymphocytes after CCRT exhibited better survival than other groups (decrease or no change) (p ¼ 0.017). Conclusions: Increase in CD8þ lymphocyte density improved OS. Because this study was performed with small number of patients, prognostic value of PD-L1 in this group of patients should be considered for future treatment planning or study design although it was not statistically significant in this study. Legal entity responsible for the study: Yonsei Cancer Center. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
1376P The standard of care for stage III NSCLC in the era of immunotherapy:
An Italian national survey on the current pattern of care among Italian thoracic oncologists Results: 421 responses were analyzed;69% of responders had more than 5 years experience in thoracic oncology. In 72% of Centers, TO regularly attend a weekly multidisciplinary Team (MDT) meeting, while in 28% MDT is not regularly planned. About pathology, cytological/histological morphologic diagnosis of malignancy were considered enough to define a therapeutic approach in 63% of responders. In N2, Stage IIIA, "minimal" pts upfront surgery was considered the preferred option from 43% of responders, while in N2, multi-nodal and/or bulky pts cCRT was recommended. For this latter group ("unresectable") only 54% considered cCRT the most appropriate choice, while 46% preferred a sequential chemo-RT, even in fit pts due to better pts compliance and lower toxicity profiles. Conclusions: Our analysis showed an inhomogeneous scenario between different specialists regarding the appropriate therapeutic choices for LA-NSCLC treatment. Additionally, some discrepancies were found about a correct selection of pts fit for cCRT. Many efforts have to be put towards the increase of a true multidisciplinarity, since in many Institutions lack of MDT was described. Future investigations and trials are necessary to optimize treatment approaches in LA-NSCLC, in particular considering recent clinical results on combination of cCRT and IT. Legal entity responsible for the study: Alessio Bruni. Funding: AstraZeneca. Disclosure: All authors have declared no conflicts of interest. 
